Posted by Michael Wonder on 21 Jun 2022
AbbVie submits supplemental new drug application to U.S. FDA for atogepant (Qulipta) to support label expansion for the preventive treatment of migraine
21 June 2022 - Submission is based on pivotal Phase 3 PROGRESS chronic migraine study evaluating atogepant (Qulipta) in adult patients that met primary endpoint of statistically significant reduction from baseline in mean monthly migraine days compared to placebo.
AbbVie today announced that it has submitted a supplemental new drug application for atogepant (Qulipta) to the U.S. FDA to support the preventive treatment of chronic migraine in adults.
